JPS56108712A - Lecithin cholesterol acyl transferase activator - Google Patents

Lecithin cholesterol acyl transferase activator

Info

Publication number
JPS56108712A
JPS56108712A JP1073780A JP1073780A JPS56108712A JP S56108712 A JPS56108712 A JP S56108712A JP 1073780 A JP1073780 A JP 1073780A JP 1073780 A JP1073780 A JP 1073780A JP S56108712 A JPS56108712 A JP S56108712A
Authority
JP
Japan
Prior art keywords
lecithin
pantethine
activator
lcat
acyl transferase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP1073780A
Other languages
Japanese (ja)
Other versions
JPS6345371B2 (en
Inventor
Toyoichiro Murata
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Pharmaceutical Co Ltd
Original Assignee
Daiichi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Pharmaceutical Co Ltd filed Critical Daiichi Pharmaceutical Co Ltd
Priority to JP1073780A priority Critical patent/JPS56108712A/en
Publication of JPS56108712A publication Critical patent/JPS56108712A/en
Publication of JPS6345371B2 publication Critical patent/JPS6345371B2/ja
Granted legal-status Critical Current

Links

Landscapes

  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

PURPOSE:The titled activator that uses pantethine and lecithin as effective components, thus being effective on coronary arteriosclerosis. CONSTITUTION:Pantethine and lecithine are used as effective components to produce a lecithin chloesterol acyl transferase activator (abbreviated to LCAT). Patients with coronary arterioscelerosis, renal diseases or diabetes are observed to have activity-lowered LCAT in blood and the combined administration of pantethine together with lecithin has been found to increase the LCAT activity remarkably. Therefore, the combination is expected to be effective on these diseases. Usually, 1,000-2,000mg of pantethine and 5-7g of lecithin are orally administered a day.
JP1073780A 1980-01-31 1980-01-31 Lecithin cholesterol acyl transferase activator Granted JPS56108712A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP1073780A JPS56108712A (en) 1980-01-31 1980-01-31 Lecithin cholesterol acyl transferase activator

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP1073780A JPS56108712A (en) 1980-01-31 1980-01-31 Lecithin cholesterol acyl transferase activator

Publications (2)

Publication Number Publication Date
JPS56108712A true JPS56108712A (en) 1981-08-28
JPS6345371B2 JPS6345371B2 (en) 1988-09-09

Family

ID=11758600

Family Applications (1)

Application Number Title Priority Date Filing Date
JP1073780A Granted JPS56108712A (en) 1980-01-31 1980-01-31 Lecithin cholesterol acyl transferase activator

Country Status (1)

Country Link
JP (1) JPS56108712A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995034811A1 (en) * 1993-06-11 1995-12-21 Oculon Corporation Protein condensation inhibitors and methods related thereto
WO2015050148A1 (en) * 2013-10-04 2015-04-09 第一三共株式会社 3-arylpyrazolopyridine derivative
WO2015076353A1 (en) * 2013-11-25 2015-05-28 第一三共株式会社 3-alkylpyrazolopyridine derivative

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995034811A1 (en) * 1993-06-11 1995-12-21 Oculon Corporation Protein condensation inhibitors and methods related thereto
WO2015050148A1 (en) * 2013-10-04 2015-04-09 第一三共株式会社 3-arylpyrazolopyridine derivative
WO2015076353A1 (en) * 2013-11-25 2015-05-28 第一三共株式会社 3-alkylpyrazolopyridine derivative

Also Published As

Publication number Publication date
JPS6345371B2 (en) 1988-09-09

Similar Documents

Publication Publication Date Title
CA2047686A1 (en) Dietary supplement for insulin-resistant diabetics
EP0151989A3 (en) Means for the treatment of cardiac diseases
ATE204178T1 (en) METHOD FOR TREATING AND PREVENTING TYPE 1 DIABETIS BY ORAL ADMINISTRATION OF INSULIN
NO951592L (en) Process for the preparation of a transdermal therapeutic system
ATE66614T1 (en) INSULIN PREPARATION FOR NON-PARENTERAL ADMINISTRATION.
AU2506388A (en) Azelastine-containing medicaments for application in the nose and/or at the eye
ES8201596A1 (en) their preparation and use as medicines.
PL287844A1 (en) Method of obtaining an oraly administered composite medicine for treating interstinal inflamatory diseases
DE3575076D1 (en) CATHETER FOR BACK INFUSION OF PHARMACEUTICAL AGENTS.
ATE65696T1 (en) USE OF DEFIBROTID IN THE TREATMENT OF ACUTE KIDNEY FAILURE CONDITIONS.
ATE65912T1 (en) MEDICINAL COMPOSITIONS OF REDUCED TOXICITY.
EP0302714A3 (en) Pharmaceutical composition for treatment of bone-wasting diseases
JPS56108712A (en) Lecithin cholesterol acyl transferase activator
FR2362849A1 (en) NEW HETEROCYCLO-OMEGA-PENTANORPROSTAGLANDINS ARYLIC SUBSTITUTES IN POSITION 2 AND MEDICINAL PRODUCTS CONTAINING THEM
FR2428649A1 (en) DIESTERS IN 17,21 OF HYDROCORTISONE AND MEDICINAL PRODUCTS CONTAINING SAME
EG17992A (en) Preparation of a medicament for arthritis and theumatism
NO862321D0 (en) PHYSIOLOGICAL AGENT FOR INCREASING TRANSDERMAL DELIVERY OF MEDICINAL PRODUCTS.
MY114218A (en) The use of bambuterol or a pharmaceutically acceptable salt thereof, to make lipid lowering pharmaceutical preparations.
KR880010762A (en) Composition and Method for Treatment of peptic Ulcers
ATE55254T1 (en) REDUCING THE TOXIC EFFECTS OF ANTHRACHINONE MEDICATIONS.
SU637117A1 (en) Method of tuberculosis diagnosis
Rich et al. Agranulocytosis resulting from methimazole (tapazole): report of three cases
熊宁宁 et al. EFFECTS OF TCM THERAPY ON THE PROGRESSION OF CHRONIC RENAL FAILURE CAUSED BY PRIMARY GLOMERULONEPHRITIS
Cidad Metabolic effects of beta-blocking drugs. Their association with diuretics in the treatment of arterial hypertension.
UA15281A (en) Method for treatment of chronic coronary heart disease